Patent · US Active

Engineered anti-IL-23p19 antibodies

US9809648B2 · kind B2 · utility

0Cited by
8References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 17, 2012
Grant dateNov 7, 2017
Priority date—
Expiry dateOct 17, 2033

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/76
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.